MediWound Q1 Earnings Call Highlights

MediWound reported a wider first-quarter loss and lower revenue versus the prior-year period, a negative read on near-term operating performance. Management reaffirmed its 2026 revenue outlook and said it is continuing to advance EscharEx and NexoBrid, which helps offset the weaker quarterly results. The update is likely to affect the stock, but the reaffirmed long-term outlook limits the downside.

Analysis

MediWound reported a wider first-quarter loss and lower revenue versus the prior-year period, a negative read on near-term operating performance. Management reaffirmed its 2026 revenue outlook and said it is continuing to advance EscharEx and NexoBrid, which helps offset the weaker quarterly results. The update is likely to affect the stock, but the reaffirmed long-term outlook limits the downside.